title: SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
abstract: ObjectiveSENTINEL1 characterized U.S. preterm infants 29 to 35 weeks' gestational age (wGA) < 12 months old hospitalized for laboratory-confirmed respiratory syncytial virus (RSV) disease and not receiving RSV immunoprophylaxis during the 2014 to 2015 RSV season.Study DesignThis is a noninterventional, observational, cohort study.ResultsA total of 702 infants were hospitalized with community-acquired RSV disease, of whom an estimated 42% were admitted to the intensive care unit (ICU) and 20% required invasive mechanical ventilation (IMV). Earlier gestational age and younger chronologic age were associated with an increased frequency of RSV-confirmed hospitalization (RSVH), ICU admission, and IMV. Among infants 29 to 32 wGA and < 3 months of age, 68% required ICU admission and 44% required IMV. One death occurred of an infant 29 wGA. Among the 212 infants enrolled for in-depth analysis of health care resource utilization, mean and median RSVH charges were $55,551 and $27,461, respectively, which varied by intensity of care required. Outpatient visits were common, with 63% and 62% of infants requiring visits before and within 1 month following the RSVH, respectively.ConclusionPreterm infants 29 to 35 wGA are at high risk for severe RSV disease, which imposes a substantial health burden, particularly in the first months of life.
authors.affiliation: Departments of Pediatrics and Medicine, Emory University School of Medicine, Atlanta, Georgia.
authors.forename: Evan J
authors.initials: EJ
authors.lastname: Anderson
authors.affiliation: Department of Pediatrics, Winthrop University Hospital, Mineola, New York.
authors.forename: Leonard R
authors.initials: LR
authors.lastname: Krilov
authors.affiliation: Department of Pediatrics, CFRI at Le Bonheur Children's Hospital, University of Tennessee Center for Health Sciences, Memphis, Tennessee.
authors.forename: John P
authors.initials: JP
authors.lastname: DeVincenzo
authors.affiliation: Department of Pediatrics, Texas Children's Hospital, Houston, Texas.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Checchia
authors.affiliation: Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
authors.forename: Natasha
authors.initials: N
authors.lastname: Halasa
authors.affiliation: Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.
authors.forename: Eric A F
authors.initials: EA
authors.lastname: Simões
authors.affiliation: Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York.
authors.forename: Joseph B
authors.initials: JB
authors.lastname: Domachowske
authors.affiliation: Department of Pediatrics, Akron Children's Hospital, Akron, Ohio.
authors.forename: Michael L
authors.initials: ML
authors.lastname: Forbes
authors.affiliation: Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California.
authors.forename: Pia S
authors.initials: PS
authors.lastname: Pannaraj
authors.affiliation: Department of Statistics, United BioSource Corporation, Ann Arbor, Michigan.
authors.forename: Scott J
authors.initials: SJ
authors.lastname: McBride
authors.affiliation: Department of U.S. Medical Affairs, AstraZeneca, Gaithersburg, Maryland.
authors.forename: Kimmie K
authors.initials: KK
authors.lastname: McLaurin
authors.affiliation: Department of U.S. Medical Affairs, AstraZeneca, Gaithersburg, Maryland.
authors.forename: Veena R
authors.initials: VR
authors.lastname: Kumar
authors.affiliation: Department of U.S. Medical Affairs, AstraZeneca, Gaithersburg, Maryland.
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Ambrose
mesh_terms: D000553:Ambulatory Care / Q000191:economics / Q000706:statistics & numerical data*; D000998:Antiviral Agents / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D005865:Gestational Age; D017048:Health Care Costs; D017721:Hospital Costs; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D015278:Intensive Care Units, Pediatric; D008297:Male; D000069455:Palivizumab / Q000627:therapeutic use; D012121:Respiration, Artificial; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology* / Q000517:prevention & control; D014481:United States / Q000453:epidemiology
chemical_list: D000998:Antiviral Agents; D000069455:Palivizumab